Colorectal Cancer

Latest News

Takeda Stakes $1.13 Billion on Rights to Fruquintinib for Advanced Refractory Colorectal Cancer
Takeda Stakes $1.13 Billion on Rights to Fruquintinib for Advanced Refractory Colorectal Cancer

January 23rd 2023

Under the agreement, Takeda will pay Hutchmed $400 million up front and up to $730 million in additional potential payments relating to regulatory, development, and commercial sales milestones, as well as royalties on worldwide net sales, with the exception of mainland China, Hong Kong, and Macau.

Tucatinib Plus Trastuzumab Approved for RAS Wild-type, HER2+ Unresectable or Metastatic CRC
Tucatinib Plus Trastuzumab Approved for RAS Wild-type, HER2+ Unresectable or Metastatic CRC

January 19th 2023

Large Genome-Wide Association Study Finds Possible New Colorectal Cancer Targets
Large Genome-Wide Association Study Finds Possible New Colorectal Cancer Targets

December 22nd 2022

From Cancer Prevention to Treatment: Underpinning the Advances, Challenges to Democratizing Precision Oncology
From Cancer Prevention to Treatment: Underpinning the Advances, Challenges to Democratizing Precision Oncology

December 2nd 2022

What Does PD-L2 Tell Us About Advanced Colorectal Cancer?
What Does PD-L2 Tell Us About Advanced Colorectal Cancer?

December 30th 2020

Video Interviews

More News

© 2023 MJH Life Sciences
AJMC®
All rights reserved.